Archimedes Pharma Enrols First Patient in Phase III Programme for Nasalfent in Cancer Pain
Archimedes Pharma Ltd announced the commencement of its global Phase III programme for Nasalfent® in breakthrough cancer pain. Up to 180 patients are being recruited in a placebo controlled, randomised trial across 43 centres in the US and Canada. The endpoints will focus on assessments of pain intensity and pain relief at several time points up to 60 minutes post treatment and will provide data on the acceptability and safety of Nasalfent. The lead investigator is Russell K. Portenoy, MD, Chairman of the Department of Pain Medicine and Palliative Care at Beth Israel Medical Center, New York. Patients who successfully complete the trial will be eligible to enrol in a longer term open safety study.
Nasalfent is an fentanyl citrate nasal spray aimed at providing a fast, effective and convenient treatment for breakthrough cancer pain - sudden, unpredictable episodes of intense pain that occur despite background pain medication and which can affect up to 95% of cancer patients. Patients suffering from breakthrough cancer pain may have very limited treatment options. Fentanyl is a highly effective opiate analgesic and is seen as the drug of choice for breakthrough cancer pain because of its rapid onset and short duration of action.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.